Latham & Watkins Advises on Latigo Biotherapeutics’ Upsized US$345.6 Million Initial Public Offering
Latigo Biotherapeutics priced an upsized US$345.6 million IPO, selling 19.2 million shares at US$18 per share. All shares were offered by Latigo, with gross proceeds expected to be US$345.6 million before fees. Underwriters have a 30-day option to buy up to 2.88 million additional shares at the same price. Latham & Watkins represented the underwriters.
How this was made
The 30-second read
Why it matters
The article provides the priced terms of an upsized IPO, including the offer size, price, expected gross proceeds, and the underwriters’ over-allotment option, which are key inputs for positioning around the listing.
Market read
This is a primary disclosure of IPO economics that can drive immediate trading interest and volatility for the issuer at/around listing.
What to watch
First-day performance will depend on lockup terms, syndicate allocation, and broader biotech risk appetite, none of which are detailed here.
Background
Latigo is a clinical-stage biopharmaceutical company focused on non-opioid pain medicines.
Market effects
Adds supply of a clinical-stage non-opioid pain biotech to the public markets, which can influence sentiment toward similar pre-revenue names.
Primarily US IPO market flow and biotech risk appetite.
Limited beyond US biotech IPO sentiment.
Counterpoint
IPO pricing can be a near-term sell-the-news setup if demand was already reflected in pre-IPO indications.
Key entities
- companyLatigo Biotherapeutics, Inc.
Clinical-stage biopharmaceutical company that priced an upsized IPO.
- law_firmLatham & Watkins LLP
Represented the underwriters in the offering.
